BioLite, Inc.

Quick facts

Phase 2 pipeline

• BLEX 404 Oral Liquid · Diabetes
  BLEX 404 Oral Liquid is a small molecule that targets the SGLT2 receptor.
• PDC-1421 Capsule

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioLite, Inc. portfolio CI brief
• BioLite, Inc. pipeline updates RSS